治疗有毒肝病的西利玛林:国际共识建议
Anton Gillessen1, Francesco Angelico2, Jun Chen3
1Department of Internal Medicine, Herz-Jesu-Hospital, Muenster, Germany.
Gastro hep advances
|August 12, 2024
概括
慢性肝病 (CLD) 涵盖各种疾病,包括酒精性和非酒精性脂肪肝疾病. 氧化应激是一种常见的原因,导致专家提出将其归类为有毒肝病 (TLD),并强调西利玛林作为潜在的抗氧化剂治疗.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性肝病 (CLD) 构成了全球健康的重大负担,其中中国的份额相当大.
- 结合性肝病包括酒精性肝病,非酒精性脂肪性肝病/与代谢功能障碍相关的脂肪性肝病和药物诱导的肝损伤等疾病.
- 肝硬化,炎症和纤维化是常见的病理,如果不治疗,可能导致肝硬化.
研究的目的:
- 根据共享的病理机制,提出对肝毒性疾病 (TLD) 的统一定义.
- 评估西利马林作为TLD的肝脏保护剂的潜力.
主要方法:
- 一个国际专家小组召开会议,讨论在TLD定义下统一各种CLD表型.
- 对西利马林治疗效果的临床前和临床证据的审查.
主要成果:
- 氧化应激被确定为一种常见的病理机制,是各种有毒肝损伤的基础.
- 西利马林已经证明了已确定的抗氧化,抗炎和抗纤维作用.
- 专家小组强调了西利玛林作为TLD的抗氧化治疗的重要性.
结论:
- 毒性肝病 (TLD) 统一了基于氧化应激的酒精性肝病,NAFLD/MAFLD和DILI等疾病.
- 由于其抗氧化性质,西利玛林作为TLD的肝脏保护剂显示出希望.
相关概念视频
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
169
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
169
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
610
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
610


